Medical - Healthcare Plans
Compare Stocks
4 / 10Stock Comparison
NIVF vs TMHC vs DHI vs NTRA
Revenue, margins, valuation, and 5-year total return — side by side.
Residential Construction
Residential Construction
Medical - Diagnostics & Research
NIVF vs TMHC vs DHI vs NTRA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Healthcare Plans | Residential Construction | Residential Construction | Medical - Diagnostics & Research |
| Market Cap | $1M | $5.56B | $42.29B | $31.16B |
| Revenue (TTM) | $3M | $7.61B | $33.35B | $2.31B |
| Net Income (TTM) | $-462K | $672M | $3.17B | $-208M |
| Gross Margin | 19.9% | 22.4% | 22.8% | 64.8% |
| Operating Margin | -102.0% | 13.2% | 11.8% | -13.4% |
| Forward P/E | — | 11.2x | 13.7x | — |
| Total Debt | $3M | $2.36B | $6.03B | $214M |
| Cash & Equiv. | $458K | $851M | $2.99B | $1.08B |
NIVF vs TMHC vs DHI vs NTRA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 22 | May 26 | Return |
|---|---|---|---|
| NewGenIvf Group Lim… (NIVF) | 100 | 0.0 | -100.0% |
| Taylor Morrison Hom… (TMHC) | 100 | 218.5 | +118.5% |
| D.R. Horton, Inc. (DHI) | 100 | 195.9 | +95.9% |
| Natera, Inc. (NTRA) | 100 | 540.4 | +440.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NIVF vs TMHC vs DHI vs NTRA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NIVF lags the leaders in this set but could rank higher in a more targeted comparison.
TMHC is the clearest fit if your priority is valuation efficiency.
- PEG 0.34 vs DHI's 1.09
- Better valuation composite
DHI carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 11 yrs, beta 0.85, yield 1.1%
- Lower volatility, beta 0.85, Low D/E 24.4%, current ratio 17.39x
- Beta 0.85, yield 1.1%, current ratio 17.39x
- 9.5% margin vs NIVF's -16.5%
NTRA is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 35.9%, EPS growth 0.7%, 3Y rev CAGR 41.1%
- 20.9% 10Y total return vs DHI's 424.3%
- 35.9% revenue growth vs DHI's -6.9%
- +37.3% vs NIVF's -99.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 35.9% revenue growth vs DHI's -6.9% | |
| Value | Better valuation composite | |
| Quality / Margins | 9.5% margin vs NIVF's -16.5% | |
| Stability / Safety | Beta 0.85 vs NIVF's 1.96 | |
| Dividends | 1.1% yield; 11-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +37.3% vs NIVF's -99.3% | |
| Efficiency (ROA) | 8.9% ROA vs NIVF's -12.2%, ROIC 12.1% vs -37.7% |
NIVF vs TMHC vs DHI vs NTRA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
NIVF vs TMHC vs DHI vs NTRA — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
NTRA leads in 2 of 6 categories
DHI leads 2 • TMHC leads 1 • NIVF leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
NTRA leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
DHI is the larger business by revenue, generating $33.3B annually — 11938.0x NIVF's $3M. DHI is the more profitable business, keeping 9.5% of every revenue dollar as net income compared to NIVF's -16.5%. On growth, NTRA holds the edge at +39.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $3M | $7.6B | $33.3B | $2.3B |
| EBITDAEarnings before interest/tax | -$1M | $1.0B | $4.0B | -$310M |
| Net IncomeAfter-tax profit | -$461,617 | $672M | $3.2B | -$208M |
| Free Cash FlowCash after capex | -$7M | $710M | $3.5B | $97M |
| Gross MarginGross profit ÷ Revenue | +19.9% | +22.4% | +22.8% | +64.8% |
| Operating MarginEBIT ÷ Revenue | -102.0% | +13.2% | +11.8% | -13.4% |
| Net MarginNet income ÷ Revenue | -16.5% | +8.8% | +9.5% | -9.0% |
| FCF MarginFCF ÷ Revenue | -2.4% | +9.3% | +10.5% | +4.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -16.2% | -26.8% | -2.3% | +39.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -114.4% | -51.2% | -13.2% | +185.4% |
Valuation Metrics
TMHC leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 7.7x trailing earnings, TMHC trades at a 39% valuation discount to DHI's 12.6x P/E. Adjusting for growth (PEG ratio), TMHC offers better value at 0.23x vs DHI's 1.01x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $1M | $5.6B | $42.3B | $31.2B |
| Enterprise ValueMkt cap + debt − cash | $4M | $7.1B | $45.3B | $30.3B |
| Trailing P/EPrice ÷ TTM EPS | -0.06x | 7.65x | 12.62x | -144.62x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 11.22x | 13.71x | — |
| PEG RatioP/E ÷ EPS growth rate | — | 0.23x | 1.01x | — |
| EV / EBITDAEnterprise value multiple | — | 6.18x | 10.02x | — |
| Price / SalesMarket cap ÷ Revenue | 0.27x | 0.68x | 1.23x | 13.51x |
| Price / BookPrice ÷ Book value/share | — | 0.95x | 1.83x | 17.55x |
| Price / FCFMarket cap ÷ FCF | — | 6.88x | 12.88x | 285.53x |
Profitability & Efficiency
DHI leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
DHI delivers a 12.9% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-60 for NIVF. NTRA carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to TMHC's 0.37x. On the Piotroski fundamental quality scale (0–9), NTRA scores 5/9 vs NIVF's 2/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -59.5% | +10.8% | +12.9% | -15.3% |
| ROA (TTM)Return on assets | -12.2% | +6.9% | +8.9% | -10.6% |
| ROICReturn on invested capital | -37.7% | +11.0% | +12.1% | -36.1% |
| ROCEReturn on capital employed | -55.0% | +13.2% | +13.1% | -18.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 | 4 | 5 |
| Debt / EquityFinancial leverage | — | 0.37x | 0.24x | 0.13x |
| Net DebtTotal debt minus cash | $3M | $1.5B | $3.0B | -$862M |
| Cash & Equiv.Liquid assets | $457,740 | $851M | $3.0B | $1.1B |
| Total DebtShort + long-term debt | $3M | $2.4B | $6.0B | $214M |
| Interest CoverageEBIT ÷ Interest expense | 1.71x | 19.94x | 44.09x | -25.21x |
Total Returns (Dividends Reinvested)
NTRA leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NTRA five years ago would be worth $21,587 today (with dividends reinvested), compared to $0 for NIVF. Over the past 12 months, NTRA leads with a +37.3% total return vs NIVF's -99.3%. The 3-year compound annual growth rate (CAGR) favors NTRA at 60.6% vs NIVF's -97.8% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -84.0% | +1.1% | +0.8% | -3.9% |
| 1-Year ReturnPast 12 months | -99.3% | +2.0% | +20.3% | +37.3% |
| 3-Year ReturnCumulative with dividends | -100.0% | +37.4% | +38.6% | +314.0% |
| 5-Year ReturnCumulative with dividends | -100.0% | +85.7% | +46.7% | +115.9% |
| 10-Year ReturnCumulative with dividends | -100.0% | +321.2% | +424.3% | +2089.4% |
| CAGR (3Y)Annualised 3-year return | -97.8% | +11.2% | +11.5% | +60.6% |
Risk & Volatility
Evenly matched — DHI and NTRA each lead in 1 of 2 comparable metrics.
Risk & Volatility
DHI is the less volatile stock with a 0.85 beta — it tends to amplify market swings less than NIVF's 1.96 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NTRA currently trades 85.7% from its 52-week high vs NIVF's 0.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.96x | 0.92x | 0.85x | 1.26x |
| 52-Week HighHighest price in past year | $367.80 | $72.50 | $184.55 | $256.36 |
| 52-Week LowLowest price in past year | $0.46 | $54.58 | $114.17 | $131.81 |
| % of 52W HighCurrent price vs 52-week peak | +0.4% | +82.0% | +79.1% | +85.7% |
| RSI (14)Momentum oscillator 0–100 | 28.0 | 49.0 | 49.6 | 57.1 |
| Avg Volume (50D)Average daily shares traded | 821K | 1.1M | 2.6M | 1.3M |
Analyst Outlook
DHI leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: TMHC as "Buy", DHI as "Hold", NTRA as "Buy". Consensus price targets imply 24.0% upside for TMHC (target: $74) vs 12.3% for DHI (target: $164). DHI is the only dividend payer here at 1.09% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | — | $73.75 | $163.86 | $262.50 |
| # AnalystsCovering analysts | — | 30 | 52 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.1% | — |
| Dividend StreakConsecutive years of raises | — | 1 | 11 | — |
| Dividend / ShareAnnual DPS | — | — | $1.60 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +6.9% | +10.1% | 0.0% |
NTRA leads in 2 of 6 categories (Income & Cash Flow, Total Returns). DHI leads in 2 (Profitability & Efficiency, Analyst Outlook). 1 tied.
NIVF vs TMHC vs DHI vs NTRA: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NIVF or TMHC or DHI or NTRA a better buy right now?
For growth investors, Natera, Inc.
(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus -6. 9% for D. R. Horton, Inc. (DHI). Taylor Morrison Home Corporation (TMHC) offers the better valuation at 7. 7x trailing P/E (11. 2x forward), making it the more compelling value choice. Analysts rate Taylor Morrison Home Corporation (TMHC) a "Buy" — based on 30 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NIVF or TMHC or DHI or NTRA?
On trailing P/E, Taylor Morrison Home Corporation (TMHC) is the cheapest at 7.
7x versus D. R. Horton, Inc. at 12. 6x. On forward P/E, Taylor Morrison Home Corporation is actually cheaper at 11. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Taylor Morrison Home Corporation wins at 0. 34x versus D. R. Horton, Inc. 's 1. 09x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — NIVF or TMHC or DHI or NTRA?
Over the past 5 years, Natera, Inc.
(NTRA) delivered a total return of +115. 9%, compared to -100. 0% for NewGenIvf Group Limited (NIVF). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus NIVF's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NIVF or TMHC or DHI or NTRA?
By beta (market sensitivity over 5 years), D.
R. Horton, Inc. (DHI) is the lower-risk stock at 0. 85β versus NewGenIvf Group Limited's 1. 96β — meaning NIVF is approximately 132% more volatile than DHI relative to the S&P 500. On balance sheet safety, Natera, Inc. (NTRA) carries a lower debt/equity ratio of 13% versus 37% for Taylor Morrison Home Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — NIVF or TMHC or DHI or NTRA?
By revenue growth (latest reported year), Natera, Inc.
(NTRA) is pulling ahead at 35. 9% versus -6. 9% for D. R. Horton, Inc. (DHI). On earnings-per-share growth, the picture is similar: Natera, Inc. grew EPS 0. 7% year-over-year, compared to -279. 4% for NewGenIvf Group Limited. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NIVF or TMHC or DHI or NTRA?
D.
R. Horton, Inc. (DHI) is the more profitable company, earning 10. 5% net margin versus -9. 7% for NewGenIvf Group Limited — meaning it keeps 10. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMHC leads at 14. 0% versus -21. 4% for NIVF. At the gross margin level — before operating expenses — NTRA leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NIVF or TMHC or DHI or NTRA more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Taylor Morrison Home Corporation (TMHC) is the more undervalued stock at a PEG of 0. 34x versus D. R. Horton, Inc. 's 1. 09x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Taylor Morrison Home Corporation (TMHC) trades at 11. 2x forward P/E versus 13. 7x for D. R. Horton, Inc. — 2. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMHC: 24. 0% to $73. 75.
08Which pays a better dividend — NIVF or TMHC or DHI or NTRA?
In this comparison, DHI (1.
1% yield) pays a dividend. NIVF, TMHC, NTRA do not pay a meaningful dividend and should not be held primarily for income.
09Is NIVF or TMHC or DHI or NTRA better for a retirement portfolio?
For long-horizon retirement investors, D.
R. Horton, Inc. (DHI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 85), 1. 1% yield, +424. 3% 10Y return). NewGenIvf Group Limited (NIVF) carries a higher beta of 1. 96 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DHI: +424. 3%, NIVF: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NIVF and TMHC and DHI and NTRA?
These companies operate in different sectors (NIVF (Healthcare) and TMHC (Consumer Cyclical) and DHI (Consumer Cyclical) and NTRA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: NIVF is a small-cap quality compounder stock; TMHC is a small-cap deep-value stock; DHI is a mid-cap deep-value stock; NTRA is a mid-cap high-growth stock. DHI pays a dividend while NIVF, TMHC, NTRA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.